KR102785243B1 - 몬테루카스트 및 홍합 접착 단백질과의 조합물을 포함하는 국소 제형 - Google Patents

몬테루카스트 및 홍합 접착 단백질과의 조합물을 포함하는 국소 제형 Download PDF

Info

Publication number
KR102785243B1
KR102785243B1 KR1020207003363A KR20207003363A KR102785243B1 KR 102785243 B1 KR102785243 B1 KR 102785243B1 KR 1020207003363 A KR1020207003363 A KR 1020207003363A KR 20207003363 A KR20207003363 A KR 20207003363A KR 102785243 B1 KR102785243 B1 KR 102785243B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
montelukast
composition according
skin
mefp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207003363A
Other languages
English (en)
Korean (ko)
Other versions
KR20200039677A (ko
Inventor
벵트 잉에마르 사무엘손
밍 구
Original Assignee
장인 무코케어 파마슈티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 장인 무코케어 파마슈티컬 컴퍼니 리미티드 filed Critical 장인 무코케어 파마슈티컬 컴퍼니 리미티드
Publication of KR20200039677A publication Critical patent/KR20200039677A/ko
Application granted granted Critical
Publication of KR102785243B1 publication Critical patent/KR102785243B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020207003363A 2017-07-05 2018-07-04 몬테루카스트 및 홍합 접착 단백질과의 조합물을 포함하는 국소 제형 Active KR102785243B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/091819 2017-07-05
CN2017091819 2017-07-05
CNPCT/CN2018/087058 2018-05-16
CN2018087058 2018-05-16
PCT/CN2018/094441 WO2019007356A1 (en) 2017-07-05 2018-07-04 TOPICAL FORMULATIONS COMPRISING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS

Publications (2)

Publication Number Publication Date
KR20200039677A KR20200039677A (ko) 2020-04-16
KR102785243B1 true KR102785243B1 (ko) 2025-03-26

Family

ID=64949737

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207003363A Active KR102785243B1 (ko) 2017-07-05 2018-07-04 몬테루카스트 및 홍합 접착 단백질과의 조합물을 포함하는 국소 제형

Country Status (13)

Country Link
US (3) US11672792B2 (enExample)
EP (1) EP3648767A4 (enExample)
JP (1) JP7288404B2 (enExample)
KR (1) KR102785243B1 (enExample)
CN (3) CN113491696A (enExample)
AU (1) AU2018295944B2 (enExample)
CA (1) CA3068818A1 (enExample)
MA (1) MA52924A (enExample)
MX (1) MX2020000029A (enExample)
MY (1) MY201703A (enExample)
SG (1) SG11201911841PA (enExample)
TW (1) TWI874298B (enExample)
WO (1) WO2019007356A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201911841PA (en) * 2017-07-05 2020-01-30 Jiangyin Mucocare Pharmaceutical Co Ltd Topical formulations comprising montelukast and combinations with mussel adhesive proteins
WO2020052677A1 (en) 2018-09-14 2020-03-19 Jiangyin Usun Pharmaceutical Co., Ltd. New conjugates of montelukast and peptides
TW202042813A (zh) * 2019-01-10 2020-12-01 大陸商江陰貝瑞森製藥有限公司 含有白三烯受體拮抗劑的新穎調配物
AU2020344762A1 (en) * 2019-09-14 2022-04-14 Jiangyin Usun Pharmaceutical Co., Ltd. New peptides
US20230331792A1 (en) * 2019-12-02 2023-10-19 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides
EP4069715A4 (en) * 2019-12-02 2024-08-14 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. PEPTIDES AND THEIR USE IN THE TREATMENT OF INFLAMMATION
US12233055B2 (en) 2020-02-03 2025-02-25 Taro Pharmaceutical Industries Ltd. Topical Montelukast formulations
CN115038427A (zh) 2020-02-03 2022-09-09 塔罗制药工业有限公司 局部用孟鲁司特制剂
WO2022078772A1 (en) 2020-10-13 2022-04-21 Diomed Developments Ltd. Gel formulations comprising montelukast
CN114588267A (zh) * 2020-12-04 2022-06-07 江苏恒瑞医药股份有限公司 一种含酰胺类局部麻醉药的药物组合物
WO2022193186A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New diagnostic and therapeutic agents
WO2022193185A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New conjugates
AU2022323492A1 (en) * 2021-08-06 2024-03-21 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New treatment of immunodeficiency disorder
CN116421547A (zh) * 2023-03-09 2023-07-14 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种孟鲁司特钠外用乳膏剂的制备及其在炎症性皮肤病中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207932A1 (en) * 2002-05-03 2003-11-06 Morris Mann Compositions that prevent post-traumatic hyperpigmentation and methods related thereto
WO2007126865A2 (en) 2006-03-30 2007-11-08 Patrin Pharma Leukotriene antagonists via nasal drug delivery
WO2008106081A1 (en) 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and use for treatment or prevention of capsular contracture, scarring or hyperpigmentation
US20110124681A1 (en) 2008-05-06 2011-05-26 Schlesinger Larry S Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof
WO2017011982A1 (zh) * 2015-07-20 2017-01-26 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白产品及其抑制皮肤炎症的应用
JP6893075B2 (ja) 2014-08-04 2021-06-23 日東電工株式会社 液性免疫誘導促進用組成物及びワクチン医薬組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2156127C2 (ru) * 1995-12-28 2000-09-20 Еситоми Фармасьютикал Индустриз, Лтд. Препарат местного применения для иммуносупрессии и лечения аутоиммунных или аллергических заболеваний
CA2535029C (en) * 2003-08-07 2013-07-16 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US6987170B1 (en) * 2004-08-09 2006-01-17 Battelle Energy Alliance, Llc Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis
CN1961867A (zh) 2006-11-16 2007-05-16 徐英权 孟鲁司特钠的颗粒剂型
WO2008105803A1 (en) 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and uses thereof
CA2653011A1 (en) * 2008-12-03 2010-06-03 Apotex Technologies Inc Method and apparatus for packaging and dispensing pharmaceuticals
GB0915319D0 (en) 2009-09-03 2009-10-07 Sharma Anant Combination medicament
CN101773503A (zh) * 2010-01-12 2010-07-14 北京华禧联合科技发展有限公司 一种白三烯拮抗剂和抗组胺药组合物
EP2582373A4 (en) 2010-06-16 2013-10-30 Bruce Chandler May USE OF LEVOCETIRIZIN AND MONTELUKAST IN THE TREATMENT OF INFLUENZA, COLLECTIONS AND INFLAMMATION
CN102895661A (zh) * 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
WO2013100564A1 (ko) 2011-12-26 2013-07-04 에스케이케미칼 주식회사 몬테루카스트 또는 이의 약학적으로 허용 가능한 염을 포함한 구강투여용 필름
CN103239450B (zh) 2012-02-07 2014-11-26 齐鲁制药有限公司 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法
ES2660494T3 (es) * 2013-03-13 2018-03-22 14779507 Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática
CN103655497B (zh) 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
CN105769825A (zh) 2014-12-24 2016-07-20 广州朗圣药业有限公司 一种孟鲁司特钠的口腔膜剂及其制备方法
CN105878215A (zh) 2014-12-31 2016-08-24 天津康鸿医药科技发展有限公司 一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途
WO2016148455A2 (ko) * 2015-03-13 2016-09-22 경희대학교 산학협력단 몬테루카스트의 생체이용률을 개선시키기 위한 방법
CN104784157B (zh) 2015-04-04 2018-06-26 齐鲁制药有限公司 一种稳定的孟鲁司特口腔薄膜剂
WO2017011983A1 (zh) * 2015-07-20 2017-01-26 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白用于皮肤和皮肤附属器官的防护
EP3419676B1 (en) * 2016-02-22 2022-08-31 Board of Regents, The University of Texas System Antimicrobial compositions and uses thereof
US10548837B1 (en) 2016-05-04 2020-02-04 Taro Pharmaceutical Industries Ltd. Topical montelukast for treatment of atopic dermatitis
SG11201911841PA (en) * 2017-07-05 2020-01-30 Jiangyin Mucocare Pharmaceutical Co Ltd Topical formulations comprising montelukast and combinations with mussel adhesive proteins
MA52794A (fr) * 2018-05-28 2021-04-14 Jiangyin Usun Pharmaceutical Co Ltd Nouvelle utilisation pharmaceutique
WO2020052677A1 (en) * 2018-09-14 2020-03-19 Jiangyin Usun Pharmaceutical Co., Ltd. New conjugates of montelukast and peptides
TW202042813A (zh) * 2019-01-10 2020-12-01 大陸商江陰貝瑞森製藥有限公司 含有白三烯受體拮抗劑的新穎調配物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207932A1 (en) * 2002-05-03 2003-11-06 Morris Mann Compositions that prevent post-traumatic hyperpigmentation and methods related thereto
WO2007126865A2 (en) 2006-03-30 2007-11-08 Patrin Pharma Leukotriene antagonists via nasal drug delivery
WO2008106081A1 (en) 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and use for treatment or prevention of capsular contracture, scarring or hyperpigmentation
US20110124681A1 (en) 2008-05-06 2011-05-26 Schlesinger Larry S Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof
JP6893075B2 (ja) 2014-08-04 2021-06-23 日東電工株式会社 液性免疫誘導促進用組成物及びワクチン医薬組成物
WO2017011982A1 (zh) * 2015-07-20 2017-01-26 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白产品及其抑制皮肤炎症的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Functional materials, J. Jpn. Soc. Colour Mater.,2014 , 87 (1), pp.13-18 1부.*

Also Published As

Publication number Publication date
CN113491696A (zh) 2021-10-12
MA52924A (fr) 2021-04-28
TW201919633A (zh) 2019-06-01
CN110312513B (zh) 2022-07-08
CN110312513A (zh) 2019-10-08
JP2020527134A (ja) 2020-09-03
MX2020000029A (es) 2020-08-06
US20210145819A1 (en) 2021-05-20
EP3648767A1 (en) 2020-05-13
KR20200039677A (ko) 2020-04-16
CA3068818A1 (en) 2019-01-10
AU2018295944A1 (en) 2020-02-20
US20250302818A1 (en) 2025-10-02
EP3648767A4 (en) 2021-04-28
US20230404992A1 (en) 2023-12-21
JP7288404B2 (ja) 2023-06-07
CN115300508A (zh) 2022-11-08
MY201703A (en) 2024-03-13
WO2019007356A1 (en) 2019-01-10
AU2018295944B2 (en) 2023-12-14
SG11201911841PA (en) 2020-01-30
TWI874298B (zh) 2025-03-01
US11672792B2 (en) 2023-06-13

Similar Documents

Publication Publication Date Title
KR102785243B1 (ko) 몬테루카스트 및 홍합 접착 단백질과의 조합물을 포함하는 국소 제형
US12129313B2 (en) Anti-inflammatory use of peptide
JP7742226B2 (ja) 新たな医薬品使用
JP7759693B2 (ja) モンテルカストおよびペプチドの新規接合体
KR20210114962A (ko) 류코트리엔 수용체 길항제를 함유하는 신규 제제
HK40058104A (en) Topical formulations comprising combinations of montelukast and mussel adhesion proteins
TWI901567B (zh) 胜肽之抗發炎用途
HK40082364A (en) Topical formulations comprising combinations of montelukast and mussel adhesion proteins
HK40014584B (en) Topical formulations comprising montelukast and combinations with mussel adhesive proteins
HK40014584A (en) Topical formulations comprising montelukast and combinations with mussel adhesive proteins
HK40011773A (en) Anti-inflammatory use of peptide
HK40011773B (zh) 肽的抗炎用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200204

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210702

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240219

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250106

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250318

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250319

End annual number: 3

Start annual number: 1

PG1601 Publication of registration